European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

ONK Therapeutics, Ltd. announced that the European Patent Office granted its licensed patent covering CISH knockout in natural killer (NK) cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from iPSCs.